Cancer statistics, 2022
Cancer statistics, 2022
复制标题
DOI：
10.3322/caac.21708
复制
发表时间：
2022-01-12
影响因子：
254.7
通讯作者：
Jemal, Ahmedin
中科院分区：
文献类型：
--
作者：
Siegel, Rebecca L.;Miller, Kimberly D.;Jemal, Ahmedin
每年，美国癌症协会都会估计美国新发癌症病例和死亡人数，并汇编基于人群的癌症发生率和结果的最新数据。发病率数据（截至2018年）由监测，流行病学和最终结果计划;国家癌症登记计划;和北美中央癌症登记协会收集。死亡率数据（截至2019年）由国家卫生统计中心收集。2022年，预计美国将发生1，918，030例新发癌症病例和609，360例癌症死亡，其中每天约有350例死于肺癌，肺癌是癌症死亡的主要原因。2014年至2018年期间，女性乳腺癌的发病率继续缓慢增长（每年增长0.5%），前列腺癌的发病率保持稳定，尽管自2011年以来晚期疾病的发病率每年增长4%至6%。因此，在过去十年中，在远处阶段诊断的前列腺癌比例从3.9%增加到8.2%。相比之下，晚期肺癌的发病率继续急剧下降，而局部分期的发病率每年突然增加4.5%，这有助于局部分期诊断的比例（从2004年的17%增加到2018年的28%）和3年相对生存率（从21%增加到31%）。死亡率模式反映了发病率的趋势，肺癌的下降速度加快，乳腺癌的下降速度减慢，前列腺癌的下降速度趋于稳定。总之，乳腺癌和前列腺癌的进展停滞不前，但肺癌的进展有所加强，与癌症筛查和/或治疗相关的医疗实践的变化相吻合。更有针对性的癌症控制干预措施和对改善早期发现和治疗的投资将有助于降低癌症死亡率。
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes. Incidence data (through 2018) were collected by the Surveillance, Epidemiology, and End Results program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2019) were collected by the National Center for Health Statistics. In 2022, 1,918,030 new cancer cases and 609,360 cancer deaths are projected to occur in the United States, including approximately 350 deaths per day from lung cancer, the leading cause of cancer death. Incidence during 2014 through 2018 continued a slow increase for female breast cancer (by 0.5% annually) and remained stable for prostate cancer, despite a 4% to 6% annual increase for advanced disease since 2011. Consequently, the proportion of prostate cancer diagnosed at a distant stage increased from 3.9% to 8.2% over the past decade. In contrast, lung cancer incidence continued to decline steeply for advanced disease while rates for localized-stage increased suddenly by 4.5% annually, contributing to gains both in the proportion of localized-stage diagnoses (from 17% in 2004 to 28% in 2018) and 3-year relative survival (from 21% to 31%). Mortality patterns reflect incidence trends, with declines accelerating for lung cancer, slowing for breast cancer, and stabilizing for prostate cancer. In summary, progress has stagnated for breast and prostate cancers but strengthened for lung cancer, coinciding with changes in medical practice related to cancer screening and/or treatment. More targeted cancer control interventions and investment in improved early detection and treatment would facilitate reductions in cancer mortality.